BCL2 and diffuse large B-cell lymphoma: In this study, we found a regimen combining BCL‐2 inhibitor ABT‐199 with tyrosine kinase inhibitor Apatinib exerting superb antitumour activity against DLBCL cells and patients, and this combination regimen showed superior effects on cells from different DLBCL subtypes carrying diverse genetic alterations in the in vitro, ex vivo.